Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 9/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704618 | 0.92 | GCK (0.37) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL3576199 | 0.81 | PPARG (0.40) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL3017912 | 0.80 | PPARA (0.37) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL3573981 | 0.78 | PPARG (0.41) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL4700751 | 0.76 | GCK (0.41) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL4700830 | 0.76 | MCHR1 (0.38) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL3569793 | 0.76 | GCK (0.40) | DGAT1PPARAPPARDKCNH2ADORA2A | |
| SCHEMBL4698138 | 0.74 | PTGES (0.44) | PPARAPPARG | |
| SCHEMBL4926766 | 0.74 | PPARG (0.44) | PPARAPPARG | |
| SCHEMBL4702217 | 0.73 | PTGES (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | DGAT1 2466/4885PPARA 1228/4885PPARD 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.